Mesa Laboratories (MLAB) Stock Price, News & Analysis

Company Overview

Mesa Laboratories, Inc. (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications. Mesa Laboratories also offers calibration standards, software platforms and technical support services that enable clients to maintain accurate instrument performance and fulfill industry-specific quality assurance requirements.

Since its founding in 1968, Mesa Laboratories has expanded through a combination of in-house research and development and strategic acquisitions to broaden its instrumentation offerings and geographic reach. The company maintains manufacturing and service facilities across North America, Europe and the Asia-Pacific region, leveraging a global distribution network to deliver products and support to customers in more than 100 countries.

Key Stats

• Today's Range: $103.61 to $107.68
• 50-Day Range: $90.80 to $109.13
• 52-Week Range: $55.45 to $113.99
• Volume: 117,341 shs
• Average Volume: 229,468 shs
• Market Capitalization: $582.58 million
• P/E Ratio: 87.95
• Dividend Yield: 0.61%
• Price Target: $94.00
• Consensus Rating: Reduce

Mesa Laboratories Stock Analysis - MarketRank™

Mesa Laboratories scored higher than 31% of companies evaluated by MarketBeat, and ranked 699th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Mesa Laboratories has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Downside Risk

Mesa Laboratories has a consensus price target of $94.00, representing about 10.9% downside from its current price of $105.54.

Amount of Analyst Coverage

Mesa Laboratories has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mesa Laboratories is 87.95, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 46.33.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mesa Laboratories is 87.95, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.75.

Price to Book Value per Share Ratio

Mesa Laboratories has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.55% of the float of Mesa Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Mesa Laboratories has a short interest ratio ("days to cover") of 0.89, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mesa Laboratories has recently decreased by 14.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Mesa Laboratories has a dividend yield of 0.61%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Mesa Laboratories does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Mesa Laboratories is 53.33%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.90

News Sentiment

Mesa Laboratories has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Mesa Laboratories this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mesa Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $770,122.00 in company stock.

Percentage Held by Insiders

4.90% of the stock of Mesa Laboratories is held by insiders.

Percentage Held by Institutions

90.60% of the stock of Mesa Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/27/2026
• Record date for 6/15 Dividend: 5/29/2026
• Ex-Dividend for 6/15 Dividend: 5/29/2026
• Dividend Payable: 6/15/2026
• Today: 7/04/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Electronic Equipment & Instruments
• Current Symbol: NASDAQ:MLAB
• CIK: 724004
• Web: www.mesalabs.com
• Phone: (303) 987-8000
• Fax: 303-987-8989
• Employees: 680
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Mesa Laboratories: $94.00
• High Price Target: $94.00
• Low Price Target: $94.00
• Potential Upside/Downside: -10.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.20
• Trailing P/E Ratio: 87.95
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $6.71 million
• Net Margins: 2.69%
• Pretax Margin: 4.82%
• Return on Equity: 20.96%
• Return on Assets: 8.78%

Debt

• Debt-to-Equity Ratio: 0.78
• Current Ratio: 1.72
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: $249.13 million
• Price / Sales: 2.34
• Cash Flow: $11.78 per share
• Price / Cash Flow: 8.96
• Book Value: $33.71 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 5,520,000
• Free Float: 5,254,000
• Market Cap: $582.58 million
• Optionable: Not Optionable
• Beta: 0.93